Green light for the second dose of AstraZeneca’s anti Covid vaccine for those who received the first without reporting rare thrombosis. This is the indication of the Scientific Technical Committee for the coronavirus emergency, contained in the opinion attached to a circular from the Ministry of Health. Object of the document, signed by the Director General for Prevention, Giovanni Rezza: ‘Transmission of the opinion of the CTS regarding the extension of the interval between the two doses of the mRna vaccines and the second dose of the Vaxzevria vaccine’. “The Cts – reads an extract from the minutes of the Committee, dated 30 April – believes that, on the basis of the information available to date on the onset of thrombosis in unusual locations (thrombosis of the cerebral venous sinuses, splanchnic thrombosis, arterial thrombosis) associated to thrombocytopenia, reported to have occurred only after the first dose of the AstraZeneca vaccine, subjects who received the first dose of this vaccine without developing this type of event have no contraindication for a second administration of the same type of vaccine. ” “This position – it is specified – could possibly be revised if different evidences emerge in the coming weeks, deriving in particular from the analysis of the safety profile of the vaccine in the subjects who received the second dose in the United Kingdom”.